Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 251-256

  Ling, Liang Han ^a   Chik, William ^a   Averbuj, Paula ^a   Pati, Purendra K ^a   Sverdlov, Aaron L ^a   Ngo, Doan T M ^a   Morris, Raymond G ^a   Sallustio, Benedetta C ^a   Horowitz, John D ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

angina pectoris; heart failure; perhexiline; pharmacokinetics; renal failure; therapeutic drug monitoring

Indexed keywords

PERHEXILINE;

ADULT; AGED; AGING; ARTICLE; BODY WEIGHT; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG MONITORING; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEADY STATE; SYSTOLIC DYSFUNCTION;

AGED; AGED, 80 AND OVER; AGING; ANGINA PECTORIS; BODY WEIGHT; CARDIOVASCULAR AGENTS; CREATININE; HUMANS; MIDDLE AGED; PERHEXILINE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79953182651     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820dd8e9     Document Type: Article

References (26)

1. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase- 1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol. 1996;52:273-280. (Pubitemid 26233756)
2. Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005; 112:3280-3288. (Pubitemid 43739373)
3. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs. 2001;1:193-204.
4. Poupon R, Rosensztajn L, Prudhomme de Saint-Maur P, et al. Prudhomme de Saint-Maur P, et al. Perhexiline maleate-associated hepatic injury prevalence and characteristics. Digestion. 1980;20:145-150. (Pubitemid 10150399)
5. Laplane D, Bousser MG. Polyneuropathy during perhexiline maleate therapy. Int J Neurol. 1981;15:293-300.
6. Cooper RG, Evans DA, Whibley EJ. Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet. 1984;21:27-33. (Pubitemid 14184360)
7. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331:442-446. (Pubitemid 18064368)
8. Amoah AG, Gould BJ, Parke DV. Single-dose pharmacokinetics of perhexiline administered orally to humans. J Chromatogr. 1984;305: 401-409. (Pubitemid 14191079)
9. Amoah AG, Gould BJ, Parke DV, et al. Further studies on the pharmacokinetics of perhexiline maleate in humans. Xenobiotica. 1986; 16:63-68. (Pubitemid 16208654)
10. Barclay ML, Sawyers SM, Begg EJ, et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics. 2003;13:627-632. (Pubitemid 37311149)
11. Sallustio BC,Westley IS, Morris RG. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol. 2002;54:107-114. (Pubitemid 35024932)
12. Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation. 1990;81:1260-1270. (Pubitemid 20119624)
13. Horowitz JD, Sia ST, Macdonald PS, et al. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol. 1986;13:219-229. (Pubitemid 16000586)
14. Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007;25:76-97. (Pubitemid 46625291)
15. deGoma EM, Vagelos RH, Fowler MB, et al. Emerging therapies for the management of decompensated heart failure: from bench to bedside. J Am Coll Cardiol. 2006;48:2397-2409. (Pubitemid 44881226)
16. Abozguia K, Elliott P, McKennaW, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562-1569.
17. Laurent-Kenesi MA, Funck-Brentano C, Poirier JM, et al. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol. 1993;36:531-538. (Pubitemid 24001714)
18. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998;34:281-302. (Pubitemid 28163404)
19. Alderman CP, Hundertmark JD, Soetratma TW. Interaction of serotonin re-uptake inhibitors with perhexiline. Aust N Z J Psychiatry. 1997;31: 601-603. (Pubitemid 27379727)
20. Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2004;76: 302-312. (Pubitemid 39313120)
21. Routledge PA, Stargel WW, Barchowsky A, et al. Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction. Br J Clin Pharmacol. 1989;28:593-597. (Pubitemid 19273608)
22. Bouche P, Bousser MG, Peytour MA, et al. Perhexiline maleate and peripheral neuropathy. Neurology. 1979;29:739-743. (Pubitemid 9135480)
23. Deschamps D, DeBeco V, Fisch C, et al. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology. 1994;19:948-961.
24. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 1995;67:101-154.
25. Said G. Perhexiline neuropathy: a clinicopathological study. Ann Neurol. 1978;3:259-266. (Pubitemid 8364356)
26. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004;2:274-302. (Pubitemid 40378782)